Sign In
Buy ADCT
$1.15
+0.0600 (+5.50%)
At Close: Jun 23, 2026
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Misses Revenue Estimates
09:35am, Thursday, 27'th Mar 2025
ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $1.03 per share a year ago.
ADC Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Operational Update
07:30am, Thursday, 27'th Mar 2025
Initial data from LOTIS-7 Phase 1b trial of ZYNLONTA® plus glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate; data update expected in second quarter 2025 Complet
ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025
05:30pm, Tuesday, 25'th Mar 2025
Oral presentation to highlight preclinical investigation of Claudin-6 ADC in ovarian and NSCLC cancer models Preclinical data for PSMA and ASCT2-targeted ADCs accepted for poster presentations LAUSANN
ADC Therapeutics: Promise Remains, But Fortunes Rest On Success Of Single Trial In 2025
11:08pm, Monday, 24'th Mar 2025
ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta, with key trials like LOTIS-5 and LOTIS-7 shaping its future prospects. Financially, ADCT holds $274.3 million
ADC Therapeutics to Host Fourth Quarter and Year-End 2024 Financial Results Conference Call on March 27, 2025
07:15am, Thursday, 20'th Mar 2025
LAUSANNE, Switzerland , March 20, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced t
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Monday, 03'rd Feb 2025
LAUSANNE, Switzerland , Feb. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
07:15am, Thursday, 30'th Jan 2025
LAUSANNE, Switzerland , Jan. 30, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:05pm, Thursday, 02'nd Jan 2025
LAUSANNE, Switzerland , Jan. 2, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced tha
LAUSANNE, Switzerland , Dec. 30, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics: Continues To Make Strides With ZYNLONTA Targeting DLBCL
02:03pm, Thursday, 12'th Dec 2024
Initial positive results released from the phase 1b study, using ZYNLONTA + COLUMVI for the treatment of patients with 2nd-line relapsed/refractory DLBCL. Additional results from the phase 1b study, u
ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate Safety data show no dose-limiting toxicities (DLTs), no high-grade cytokine release
Publication follows oral presentation at the American Society of Hematology (ASH) Annual Meeting Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95
ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial
07:30am, Friday, 06'th Dec 2024
Company to host corporate update webcast to share results on December 11, 2024 LAUSANNE, Switzerland , Dec. 6, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), today announced that it will host
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
04:30pm, Monday, 02'nd Dec 2024
LAUSANNE, Switzerland , Dec. 2, 2024 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced th
ADC Therapeutics SA (ADCT) Q3 2024 Earnings Call Transcript
11:01am, Saturday, 09'th Nov 2024
ADC Therapeutics SA (NYSE:ADCT ) Q3 2024 Results Conference Call November 7, 2024 8:30 AM ET Company Participants Marcy Graham - Investor Relations Ameet Mallik - Chief Executive Officer Pepe Carmona
